Company of the week: Harbour BioMed

Company Overview and Technology

Harbour BioMed ("HBM"; HKEX: 02142) is a global biopharmaceutical company headquartered across Shanghai, Natick (Massachusetts) and Rotterdam (Netherlands), committed to the discovery, development and commercialisation of novel antibody therapeutics in immunology and oncology. Founded in 2016 by Dr. Jingsong Wang, a former Harvard Medical School fellow and ex-Sanofi executive, the company has grown from a single transgenic mouse platform into a diversified antibody engine with a proprietary discovery platform, a clinical-stage pipeline, and a rapidly scaling out-licensing business.

At its core, Harbour BioMed operates a dual-engine business model: Harbour Therapeutics, which advances the company's own clinical pipeline; and Nona Biosciences, established in 2022 as a platform services subsidiary offering integrated antibody discovery, engineering and development solutions to external partners ranging from academic institutions to multinational pharmaceutical companies. As of early 2026, the Harbour Mice® platform has been adopted by over 100 leading global institutions, more than 19 molecules discovered through partnerships have progressed to IND-enabling stage globally, and the company has established approximately 50 partnership agreements — around 30 of which are out-licensing transactions with overseas pharmaceutical companies, including AstraZeneca, Pfizer, BMS and AbbVie.

The company's transformation into a sustainably profitable biotech engine accelerated dramatically in 2025, with a profit alert announcing full-year net profit expected between US$88 million and US$95 million — compared to approximately US$2.7 million in 2024. This represents a roughly 33-fold increase and marks the clearest validation yet of HBM's platform-led, out-licensing business model.

How Harbour BioMed's Technology Works

The company's proprietary discovery engine is the Harbour Mice® platform, a transgenic mouse system that generates fully human monoclonal antibodies in two distinct formats:

• H2L2 (two heavy and two light chain) — the conventional antibody format, optimised for standard therapeutic applications with excellent biophysical properties, extended half-life potential and low immunogenicity.
• HCAb (heavy-chain only) — a unique single-domain format that is both smaller and more flexible, enabling engineering into novel multi-specific architectures that conventional antibodies cannot achieve.

Building on the HCAb format, HBM has developed two downstream platform technologies:

HBICE® (HCAb-based Immune Cell Engagers) — a bispecific antibody technology that harnesses HCAb antibodies to engage and redirect immune effector cells (particularly T cells) against tumour targets or pathogenic cell populations. The single-domain nature of the HCAb moiety enables tumour-killing effects that traditional combination therapies or conventional bispecific designs cannot replicate.

HBICA™ (HCAb-based Bispecific Immune Cell Antagonist) — a more recent technology adapted for immunological and inflammatory diseases, enabling the simultaneous blockade of two immune-activating pathways with a single molecule.

Integrated with a single B-cell cloning platform, the full discovery engine allows rapid generation, screening and engineering of next-generation therapeutic antibodies with high efficiency. The company has extended this into a Harbour Mice® 2.0 next-generation platform and is actively expanding into antibody-drug conjugates (ADCs) and T-cell engager modalities, as reflected in its 2025 AstraZeneca expansion.

HBM's Nona Biosciences subsidiary offers these capabilities commercially as an "Idea to IND" (I to I™) service — providing one-stop discovery, protein engineering, antibody-drug conjugation, HCAb-CAR screening and drug delivery solutions to industry clients.

Leadership and Governance

Dr. Jingsong Wang (MD, PhD) serves as Founder, Chairman and CEO. Prior to founding HBM, he was Head of China R&D and Head of Translational Medicine, Asia Pacific at Sanofi, and is a former attending physician and clinical fellow at Harvard Medical School. He holds a PhD in Molecular Pharmacology from China Pharmaceutical University and completed a Molecular Immunology Research Fellowship at Harvard School of Public Health. Wang has been the principal architect of HBM's technology-platform-first strategy and its transformation into a global licensing engine.

Dr. Yiping Rong serves as Chief Scientific Officer, bringing approximately 20 years of biomedical research and drug discovery experience from Sanofi, Johnson & Johnson and Roche. He has contributed to more than 15 programs entering clinical trials.

The executive team reflects HBM's multinational character, with operations led across China, the US and the Netherlands. The company operates under a standard Hong Kong-listed corporate governance framework with an independent board committee structure.

Harbour BioMed was incorporated in 2016 and listed on the HKEX Main Board under stock code 02142. The company established its Shanghai R&D hub early, followed by the Natick (Massachusetts) and Rotterdam (Netherlands) offices that give it genuine tri-continental reach. Nona Biosciences was formally established as a wholly-owned platform services subsidiary in 2022, providing strategic separation between the therapeutic pipeline (Harbour Therapeutics) and the platform collaboration business (Nona Biosciences). As of early 2026, the company employs approximately 210 people and maintains a market capitalisation of approximately HK$10 billion (~US$1.3 billion).

Clinical Development and Pipeline

Harbour BioMed's pipeline spans autoimmune diseases, immuno-oncology and inflammation, with its most advanced assets in late-stage development. Key programs:

Batoclimab (HBM9161) — anti-FcRn mAb, autoimmune diseases. Batoclimab is HBM's most clinically advanced proprietary asset. It is a fully human anti-FcRn (neonatal Fc receptor) monoclonal antibody that blocks FcRn-IgG interactions, accelerating the degradation of pathogenic autoantibodies. It holds the distinction of being the first anti-FcRn monoclonal antibody to complete Phase I to pivotal trials in China. Batoclimab received Breakthrough Therapy designation from the NMPA in 2021 and completed a positive Phase III trial for generalised myasthenia gravis (gMG). The BLA was resubmitted to the NMPA in June 2024 (including extended long-term safety data), accepted in July 2024, and its Phase III results were published in JAMA Neurology in March 2024. HBM licensed batoclimab from HanAll Biopharma for Greater China rights, and has a co-development agreement with CSPC Group's subsidiary NBP Pharma for Chinese commercialisation, under which HBM receives tiered royalties on net sales.

Porustobart (HBM4003) — anti-CTLA-4 HCAb, immuno-oncology. Porustobart is the first fully human heavy-chain-only antibody to enter clinical development globally and represents HBM's flagship internally-discovered therapeutic. It is a next-generation CTLA-4 antibody with important differentiation from ipilimumab and tremelimumab: by leveraging the HCAb format with enhanced ADCC activity, porustobart selectively depletes intratumoral Treg cells, aiming to overcome the safety and efficacy limitations of conventional CTLA-4 therapy. HBM has implemented a multi-tumour global development plan with an adaptive design. Positive efficacy and safety data have been observed in monotherapy for advanced solid tumours, and in combination with PD-1 inhibitors for melanoma, colorectal cancer (CRC), hepatocellular carcinoma (HCC) and neuroendocrine neoplasms (NEN). In October 2025, HBM reported positive Phase II results for the combination of porustobart and tislelizumab (BeiGene's PD-1 antibody) in microsatellite stable (MSS) metastatic CRC — a population known to be resistant to single-agent PD-1 blockade. The multicenter Phase II study enrolled 24 heavily pretreated patients; the combination achieved a 34.8% objective response rate with a median progression-free survival of 4.2 months, with a manageable safety profile. Final data from the HCC combination study were published in Clinical Cancer Research in August 2025. In February 2026, HBM out-licensed ex-Greater China rights to porustobart to Solstice Oncology, a newly formed company backed by a syndicate of major venture capital investors, receiving upfront consideration valued at over US$105 million (comprising US$50 million cash, US$5 million near-term payments and US$50 million+ equity in Solstice), plus up to approximately US$1.1 billion in additional milestones and tiered royalties. Notably, HBM co-founded Solstice alongside the VC syndicate and becomes a shareholder — a structure designed for long-term value participation rather than a simple one-time licensing transaction.

HBM9378 — anti-TSLP mAb, asthma and COPD. HBM9378 is a fully human H2L2 antibody targeting TSLP (thymic stromal lymphopoietin), a validated cytokine central to type 2 inflammatory diseases including asthma and COPD. Co-developed with Sichuan Kelun-Biotech, the asset completed Phase I in China and received NMPA IND approval for COPD in early 2025. In January 2025, HBM and Kelun-Biotech out-licensed global rights (excluding Greater China and select Asian territories) to Windward Bio, which initiated the global Phase 2 POLARIS trial in July 2025. Initial data are expected by mid-2026. HBM9378 has been engineered for extended half-life and effector silencing.

HBM7020 — BCMA x CD3 bispecific T-cell engager, autoimmune diseases. Generated using the HBICE® platform, HBM7020 crosslinks targeted B cells and T cells via BCMA and CD3 binding, enabling potent T-cell-mediated elimination of pathogenic B cells driving autoimmune conditions. In June 2025, HBM out-licensed HBM7020 outside China to Otsuka Pharmaceutical, receiving US$47 million in upfront and near-term payments plus up to US$623 million in further milestones.

HBM1020 — anti-B7H7/HHLA2 mAb, oncology. A first-in-class fully human monoclonal antibody targeting B7H7/HHLA2, a newly identified B7 family immune checkpoint with non-overlapping expression with PD-L1 across multiple tumour types. This program targets a patient segment potentially refractory to existing PD-1/PD-L1 therapies.

HBM7575 — TSLP x undisclosed bispecific, inflammatory diseases. Global-rights bispecific program in the discovery/preclinical stage, targeting inflammatory disease applications.

Pipeline Summary

In addition to these proprietary programs, Nona Biosciences has enabled more than 19 partner-driven molecules to reach IND stage globally, with partnerships spanning oncology, autoimmune disease, ophthalmology and animal health.

R&D Capabilities and Collaborations

HBM's discovery infrastructure spans three primary sites: Shanghai (principal R&D, discovery biology, antibody engineering), Cambridge, Massachusetts (US scientific operations and business development), and Rotterdam, Netherlands (European scientific operations). A co-located innovation centre is being established in Beijing in partnership with AstraZeneca. Nona Biosciences operates globally as a platform services entity, providing integrated antibody discovery to external partners.

Key capabilities include: transgenic mouse generation and maintenance (Harbour Mice® H2L2 and HCAb), single B-cell cloning and high-throughput screening, protein engineering, bispecific and multi-specific antibody construction, antibody-drug conjugate chemistry, HCAb-CAR cell screening, and early-stage IND-enabling CMC.

In March 2025, HBM launched Élancé Therapeutics, an incubated spin-out focused on T-cell engager programs for autoimmune diseases, leveraging the HBICE® bispecific platform. This reflects HBM's broader strategy of incubating focused entities around specific platform applications rather than advancing all programs in-house.

In February 2025, HBM entered a strategic collaboration with Insilico Medicine — notably a company with ties to Sebastian's own network — combining Insilico's generative AI platform with HBM's antibody discovery capabilities to accelerate novel therapeutic antibody identification. In November 2025, Nona Biosciences signed a non-exclusive licensing agreement with Pfizer granting Pfizer global access to the HCAb platform for preclinical antibody discovery across multiple disease indications. In December 2024, Nona Biosciences entered a collaboration with Kodiak Sciences to discover novel multi-target antibodies for ophthalmic diseases using the Harbour Mice® platform.

The company's collaboration model has become a recurring revenue engine: by providing platform access, co-discovery services and milestone-linked licensing, HBM converts its technological capabilities into predictable cash flows without ceding full ownership of its core IP.

Financial Position as of Early 2026

Revenue, Profitability and Cash

HBM's financial trajectory has undergone a dramatic reversal over the past 18 months, moving from a loss-making development-stage company into a consistently profitable platform business. The key figures:

Revenue in H1 2025 grew 327% year-on-year, driven by licensing milestones from the AstraZeneca deal, Otsuka collaboration, and recurring platform-based research revenue. The FY2025 profit alert, issued in February 2026, confirmed full-year net profit of US$88–95 million — roughly 33x the US$2.7 million earned in FY2024. The company maintained a cash position of approximately US$320 million as of June 2025, a 92% increase from year-end 2024.

The profit growth is attributable to three sources: (1) growing recurring revenue from platform-based research collaborations with AstraZeneca, BMS and Pfizer; (2) milestone inflows from advancing clinical programs; and (3) upfront payments from out-licensing transactions. Management explicitly describes this as a "sustainable financial foundation" rather than a one-time event.

Stock and Market Capitalisation

HBM trades on the HKEX under stock code 02142. As of early January 2026, the stock was priced at approximately HK$1.55 per share (HKD), with a market capitalisation of approximately HK$10 billion (~US$1.3 billion), and trailing twelve-month revenues of approximately US$116 million. The company repurchased 8,146,000 shares in 2025 for approximately HK$30 million, reflecting management's view that the market has not fully priced in the intrinsic value of its platform.

Notably, AstraZeneca subscribed to newly issued shares representing 9.15% of HBM's equity at approximately US$105 million as part of the March 2025 collaboration — a significant strategic endorsement at an implied valuation materially above market prices at the time of writing.

Partnerships, Licensing, and Alliances

HBM's out-licensing and collaboration strategy has become central to both its scientific and financial model. The company has established approximately 50 partnership agreements to date, with the majority executed since 2022.

AstraZeneca (March 2025 + November 2025 extension) — HBM's flagship partnership. AstraZeneca committed to a global strategic collaboration to discover and develop next-generation multi-specific antibodies for immunology, oncology and beyond. Financial terms include US$175 million in upfront payments, near-term milestone payments and option fees, plus up to US$4.4 billion in development and commercial milestones and tiered royalties — bringing the total potential deal value to approximately US$4.575 billion. AstraZeneca also made an equity investment of US$105 million, acquiring 9.15% of HBM's newly issued shares, and is co-locating an innovation centre in Beijing. In November 2025, the collaboration was extended by four years to cover ADC and T-cell engager discovery programs in oncology, under equivalent financial terms.

Bristol Myers Squibb (December 2025) — A multi-year global collaboration to discover and develop next-generation multi-specific antibodies. HBM is eligible to receive US$90 million in payments plus up to US$1.035 billion in development and commercial milestones, with tiered royalties. The deal also leverages HBM's early-stage clinical trial capabilities in China.

Otsuka Pharmaceutical (June 2025) — Out-licensing of HBM7020 (BCMA x CD3 bispecific) for development and commercialisation outside China. US$47 million in upfront and near-term payments, plus up to US$623 million in further milestones and royalties.

Solstice Oncology (February 2026) — Exclusive ex-Greater China license for porustobart (HBM4003). HBM co-founded Solstice alongside a VC syndicate, receiving upfront consideration valued at over US$105 million (cash plus equity in Solstice), with up to approximately US$1.1 billion in additional milestones and royalties. HBM becomes a shareholder in Solstice, creating ongoing upside participation beyond the licensing economics.

Windward Bio / Kelun-Biotech (January 2025) — Exclusive global license (excluding Greater China and select Asian territories) for HBM9378/WIN378. Windward Bio initiated the Phase 2 POLARIS asthma trial in July 2025.

Pfizer / Nona Biosciences (November 2025) — Non-exclusive license granting Pfizer global access to the HCAb platform for preclinical antibody discovery across multiple disease indications, with Nona providing co-discovery and engineering services.

Lannacheng Biotechnology (December 2025) — Long-term strategic collaboration with Yantai Lannacheng to advance next-generation radionuclide drug conjugates (RDCs). The partnership leverages HBM's HCAb antibodies — which are approximately half the size of conventional IgGs and offer superior tissue penetration and specificity — to enhance targeted radionuclide delivery in oncology. This positions HBM in the fast-growing RDC/radiopharmaceutical space alongside its ADC and T-cell engager activities.

Spruce Biosciences / HBM Alpha Therapeutics (January 2026) — HBM exercised a warrant to acquire approximately 3.8% of outstanding shares in Nasdaq-listed Spruce Biosciences (SPRB) in January 2026, through its incubated subsidiary HBM Alpha Therapeutics (HBMAT). The underlying collaboration relates to SPR202 (formerly HBM9013), a potent anti-corticotropin-releasing hormone (CRH) monoclonal antibody being developed for congenital adrenal hyperplasia and related disorders. The warrant exercise converts the relationship from licensor-licensee to a structurally aligned strategic partnership.

Insilico Medicine (February 2025) — AI-powered antibody discovery collaboration combining Insilico's generative AI with HBM's Harbour Mice® platform.

Kodiak Sciences (December 2024) — Nona Biosciences collaboration to discover multi-target antibodies for ophthalmic diseases.

CSPC Group/NBP Pharma (October 2022) — Co-development of batoclimab in Greater China. CSPC-NBP leads Chinese commercialisation; HBM receives tiered royalties on net sales.

As with all biobucks-heavy deals, the headline values depend on successful clinical, regulatory and commercial outcomes over many years. The guaranteed upfront and near-term components are a fraction of the announced totals.

Market Positioning and Competition

Market context: The global antibody therapeutics market is one of the largest and fastest-growing segments in biopharma, driven by the success of monoclonal antibodies, bispecifics and emerging multi-specific formats. Bispecific antibodies are among the fastest-growing sub-segments, with multiple approvals since 2022 (e.g. Teclistamab, Talvey, Mosunetuzumab, Epcoritamab) and significant pipeline investment from Big Pharma. The market for antibody discovery platforms and enabling technologies is additionally driven by the growing willingness of established pharma companies to out-source early discovery to specialist partners — a trend heavily evidenced by HBM's own deal history.

Competitors in platform/CRO-like space: HBM competes with Ligand Pharmaceuticals, AbCellera Biologics (TSX: ABCL), Twist Bioscience, Sanofi's Ablexis, Humanigen and others for platform licensing revenues. Transgenic mouse platform providers with broad pharma adoption include Regeneron's VelociMune, AstraZeneca-owned Alloy Therapeutics, and Merus. Nona Biosciences faces competition from contract discovery organisations such as WuXi Biologics, Lonza and various CROs offering antibody discovery services.

Competitors in clinical pipeline: In CTLA-4 (porustobart), the key comparators are ipilimumab (Bristol Myers Squibb, approved), tremelimumab (AstraZeneca, approved for HCC in combination) and botensilimab (Agenus, late-stage). In anti-TSLP (HBM9378), the benchmark is tezepelumab (AstraZeneca/Amgen, Tezspire, approved), with competition from dupilumab (Sanofi/Regeneron, approved) for type 2 inflammation broadly. In anti-FcRn (batoclimab), the competitive set includes efgartigimod (argenx, approved), rozanolixizumab (UCB, approved) and nipocalimab (J&J, late-stage).

Position: HBM occupies an increasingly distinctive position as one of the few Chinese biotechs with both a genuine proprietary discovery platform and a growing roster of Big Pharma out-licensing relationships. The company is neither a pure-play clinical stage biotech nor a pure CRO; rather, it is building a hybrid model that captures upstream platform value (like AbCellera or Ligand) while also advancing a proprietary pipeline (like a traditional biotech). This dual-engine model — if successfully executed — provides both near-term recurring revenue from platform collaborations and long-term value from self-owned assets reaching approval.

Regulatory Affairs

Batoclimab (HBM9161): HBM's most advanced regulatory program. The BLA for gMG in China was first accepted in June 2023, then voluntarily resubmitted with additional long-term safety data and re-accepted in July 2024. As of early 2026, the NMPA review is ongoing. This is HBM's first and only BLA submission to date, and a positive decision would mark the company's transition from a development-stage to a commercial-stage company in China, at least in a co-commercialisation capacity with CSPC.

Porustobart (HBM4003): Multiple IND-cleared Phase I and Phase II trials are underway in China across solid tumour indications. No US IND or European CTA has been reported publicly. Ex-China development is proceeding under Solstice Oncology's stewardship.

HBM9378: NMPA IND approvals for asthma (2022) and COPD (early 2025). The global Phase 2 POLARIS trial, run by Windward Bio, operates under non-Chinese regulatory jurisdictions. No US IND reported publicly.

HBM7020: NMPA IND clearance for cancer Phase I received in August 2023. IND preparation underway for autoimmune indications. Out-licensed ex-China rights to Otsuka.

Platform programs: Nona Biosciences-enabled programs reach IND stage under the partners' own regulatory processes. HBM does not publicly track the regulatory status of all partner-enabled molecules.

In summary, HBM's regulatory position reflects a company on the cusp of its first commercial approval in China (batoclimab/gMG), with a clinical-stage pipeline that is predominantly in Phase I–II across its major assets. The regulatory risk remains meaningful: no product has been approved, and key trials are still mid-development.

Red Team vs. Blue Team Analysis

Risk Analysis (Red Team)

Clinical and Pipeline Risks

HBM has no marketed products. All clinical assets remain subject to mid- and late-stage development risk, and it is premature to extrapolate from Phase II signals to registration-enabling data. Porustobart's early Phase II results in MSS-CRC are encouraging, but this is a historically treatment-resistant indication where multiple promising agents have failed in Phase III. Batoclimab faces a competitive field where argenx (efgartigimod) and UCB (rozanolixizumab) are already approved and commercially established in key Western markets.

The company's revenue in 2025 is overwhelmingly dependent on out-licensing milestones and platform fees — not on clinical outcomes. This creates a divergence: HBM can appear financially strong even if its clinical programs stall, until partners begin to cut or renegotiate deals.

Concentration Risk in Platform Revenue

HBM's financial transformation is heavily dependent on the AstraZeneca collaboration, which accounts for a disproportionate share of 2025 revenue milestones. The BMS deal was signed in December 2025 and has not yet generated meaningful revenue. If AstraZeneca were to deprioritise or restructure its HBM programs — as has happened with other large platform deals — the revenue impact could be severe.

IP and Freedom to Operate

The transgenic mouse antibody platform space is densely patented. Regeneron's VelociMune has been extensively litigated. HBM must ensure that both the H2L2 and HCAb Harbour Mice® platforms are free to operate globally, particularly in the US and EU, as its out-licensing deals expand into these jurisdictions. Any IP dispute could impair the platform's commercial value at a critical period in HBM's growth.

Geopolitical and Regulatory Risk

As a Chinese-headquartered biotech with clinical programs primarily in China and partnerships with US and European pharma, HBM is exposed to the evolving US-China geopolitical landscape. US restrictions on Chinese biotech investments and data sharing (e.g. BIOSECURE Act discussions) could complicate or slow Big Pharma deals or clinical trial execution. AstraZeneca's equity stake and co-location of a Beijing innovation centre reflects confidence — but such arrangements could face scrutiny in an escalating policy environment.

Commercial Risk for Batoclimab in China

If and when batoclimab is approved for gMG in China, commercialisation will be led by CSPC/NBP, with HBM receiving tiered royalties. This means HBM has limited control over the commercial execution, pricing negotiations with the NMPA/NHSA, and potential Volume-Based Procurement dynamics that could compress realised royalties.

Opportunities and Mitigations (Blue Team)

Platform-as-a-Service Revenue Model

HBM has demonstrated, in 2025, that a transgenic antibody discovery platform can generate genuinely recurring, high-margin revenue through licensing and co-discovery agreements — not just one-time upfronts. This business model is still rare among Chinese biotechs and is more comparable to AbCellera or Ligand in Western markets. If HBM can continue to expand its collaboration network at the current rate — over 10 out-licensing deals since 2022 with a cumulative potential deal value approaching 100 billion CNY — the platform revenue could become highly predictable.

AstraZeneca as Long-Term Validator

The AstraZeneca collaboration is not merely financial — the four-year extension, the equity investment at premium valuation, and the co-located Beijing innovation centre represent a structural, long-term endorsement by one of the world's most active acquirers of Chinese biotech innovation. This provides both credibility with future partners and potential optionality for deeper strategic transactions.

Growing Bispecific and Multi-Specific Market

The next wave of antibody therapeutics is multi-specific. HBM's HBICE® and HBICA™ platforms are precisely positioned for this wave, as large pharma companies increasingly seek external partners with validated bispecific engineering capabilities. The BMS deal, focused specifically on "next-generation multi-specific antibodies," confirms demand.

Batoclimab as Pipeline-in-a-Product

If batoclimab is approved in China for gMG, HBM gains its first royalty-bearing commercial asset. Beyond gMG, batoclimab's FcRn mechanism applies broadly to pathogenic IgG-mediated autoimmune diseases — potentially including ITP, Graves' ophthalmopathy, neuromyelitis optica and others. Positive gMG approval unlocks a "pipeline in a product" strategy, with each additional indication representing incremental royalty-bearing revenue.

Porustobart Differentiation in Immuno-Oncology

The positive Phase II data in MSS-CRC — an indication where even pembrolizumab fails — is a potential proof-of-concept for porustobart's Treg-depleting mechanism. If Solstice Oncology advances this into a pivotal study and reaches approval, the milestone and royalty streams to HBM could be transformational.

Strategic Recommendations

1. Defend and deepen the AstraZeneca relationship. The AZN partnership is HBM's most strategically valuable asset. Management should prioritise delivering on discovery milestones within the Beijing co-location model, building institutional knowledge transfer that makes separation costly and unattractive.
2. Accelerate batoclimab approval and expand indications. NMPA approval of batoclimab for gMG would be a commercial and reputational milestone. HBM should engage CSPC/NBP closely on launch readiness and begin Phase II/III trials in at least one additional FcRn-relevant autoimmune indication in parallel to keep the pipeline-in-a-product narrative credible.
3. Develop US regulatory pathway for porustobart. The MSS-CRC Phase II data is a meaningful signal, but the asset's global commercial value depends on FDA approval. HBM or Solstice Oncology should initiate US IND discussions and plan a pivotal study design in consultation with FDA, given that MSS-CRC is a high unmet-need indication.
4. Formalise Nona Biosciences as a separate monetisation vehicle. Nona Biosciences has been described as a potential future standalone entity. Formalising its financial structure, establishing transparent metrics, and creating a clear pathway to an independent capital raise or HKEX listing would allow HBM to unlock platform value separately from the clinical pipeline.
5. Diversify platform partnerships beyond oncology/autoimmune. The Kodiak Sciences (ophthalmology) and animal health (Harbour Mice® has applications in veterinary biologics) directions are underexplored. Nona Biosciences could meaningfully expand its TAM by targeting mid-sized pharma and academic institutions in cardiometabolic, CNS and rare disease — areas not yet covered by HBM's current MNC partnerships.
6. Maintain financial discipline on internal pipeline. Given robust platform cash flows, HBM can afford to advance its internal therapeutic programs strategically rather than racing to Phase III internally. Selective out-licensing of ex-China rights to well-funded partners (as done with porustobart and HBM9378) is preferable to dilutive capital raises for global pivotal trials.

Scenario Analysis

Base Case: Batoclimab receives NMPA approval for gMG in 2026, generating initial royalties from CSPC/NBP. Porustobart Phase II data (HCC, CRC, NEN) attract follow-on out-licensing interest globally. AstraZeneca and BMS collaborations progress per schedule, generating recurring annual milestone payments. HBM9378/POLARIS delivers positive preliminary data in mid-2026, accelerating Windward Bio's Phase 2/3 program. Nona Biosciences continues expanding its partner network. The stock re-rates moderately higher as the company sustains profitability and approaches its first commercial royalty stream.

Best Case: Batoclimab is approved in China for gMG and initiates additional autoimmune indications, generating meaningful royalty income within 18 months. Porustobart Phase II in MSS-CRC is confirmed at a major conference and Solstice Oncology advances to a pivotal study, triggering significant milestones. AstraZeneca exercises options on multiple licensed programs, each triggering fees under the $4.4 billion framework. Nona Biosciences reaches a scale where it can be partially spun out as an independent entity, unlocking platform value. New Big Pharma partners replicate the BMS/AZN model. The stock approaches or exceeds AstraZeneca's implied entry valuation.

Worst Case: NMPA delays or rejects the batoclimab BLA, triggering a further resubmission and two additional years of wait time. AstraZeneca's nominated discovery programs fail to advance to option exercise, limiting milestone inflows beyond the upfront. Porustobart Phase II results in HCC or melanoma disappoint, causing Solstice Oncology to deprioritise the asset. The BIOSECURE Act or equivalent US legislation introduces friction for pharma-HBM collaborations, causing BMS or AZN to pause new program nominations. Revenue growth stalls; HBM remains profitable but at much lower levels; the stock gives back its 2025 gains.

Conclusion

Harbour BioMed is one of the more genuinely interesting Chinese biotechs of this cycle. Unlike the majority of its peers, which are either pure clinical-stage companies betting on a single or small number of Western-validated targets, HBM has built something structurally different: a technology platform business that generates recurring revenue from the world's largest pharmaceutical companies while simultaneously advancing a proprietary clinical pipeline.

The 2025 financial results — a 33-fold increase in net profit, a 327% revenue jump in H1, and a US$320 million cash position — are not the product of one lucky deal but of a consistent multi-year strategy. The AstraZeneca and BMS partnerships represent institutional validation at the highest level of global pharma. And critically, HBM enters 2026 within reach of its first commercial product approval in China.

The risks are real: batoclimab approval is not guaranteed, porustobart is far from pivotal trials, and the platform revenue is concentrated in a handful of large relationships. Geopolitical uncertainty around US-China biotech investment remains an overhang that the company cannot fully control.

But for anyone tracking the evolution of Chinese biopharma from a copy-and-license model toward genuine platform-driven innovation, Harbour BioMed is among the clearest examples that the transition is real.

All information in this article was accurate as of the research date and is derived from publicly available sources including company press releases, investor relations materials, regulatory announcements and financial news reporting. Information may have changed since publication. This content is for informational purposes only and does not constitute investment, legal or financial advice. The author is not a lawyer or financial adviser.